血管紧张素Ⅱ受体拮抗剂治疗血管迷走性晕厥回顾性临床疗效分析  

Retrospective Analysis to Clinic Effect of Angiotensin II Receptor Antagonist in the Treatment of Vasovagal Syncope

作　　者：黄美媚[1] 胡允兆[1] 黎宏庄[1] 欧阳基鹏[1] 李国兴[1] 黎泳欣[1] 

机构地区：[1]南方医科大学附属顺德第一人民医院,广东顺德528000

出　　处：《河北医学》2017年第1期54-57,共4页Hebei Medicine

基　　金：广东省医学科研基金;(编号:A2015613)

摘　　要：目的:回顾性分析血管紧张素Ⅱ受体拮抗剂(ARB)厄贝沙坦治疗血管迷走性晕厥临床治疗并对其与β受体阻滞剂美托洛尔的临床疗效进行观察与评价。方法:对86例经直立倾斜试验确诊的血管迷走性晕厥并分别应用美托洛尔与厄贝沙坦的患者进行回顾性分析,记录患者基线情况以及经过治疗3个月后复查倾斜试验的结果,观察阴转率及药物副作用。结果:与治疗前比较,两组患者都得到了较大的改善,其中美托洛尔组HUTT转阴率略优于厄贝沙坦组,差异有统计学意义(P<0.05),而在不良反应事件方面,厄贝沙坦组略优于美托洛尔组,差异有统计学意义(P<0.05)。结论:ARB治疗血管迷走性晕厥具有一定的疗效,相比β受体阻滞剂,其不良事件较小,是临床一种可供选择的治疗方式。Objective： Retrospective analysis to clinic effect of angiotensin II receptor antagonist （ARB） Aprovel in the treatment of Vasovagal Syncope and observe and evaluate the clinical curative effect with β blocker metoprolol. Methods： 86 cases were diagnosed by tilt table test, and retrospective analyzed the patients respectively in treatment of Aprovel and Metoprolol. Recorded the patients baseline and the tilt test re- sult after 3 months, further to observe the negative conversion rate and drug side effects. Results： Compared with those before treatment, patients in the two groups have been greatly improved, while the metoprolol group Hutt negative rate is slightly better than Aprovel group, the difference is statistically significant （P〈0.05）. In adverse reaction respect, Aprovel group was slightly better than metoprolol group, the difference is statistically significant （P〈0.05）. Conclusion： ARB has a certain effect on the treatment of patients with Vasovagal Syncope. It is a kind of alternative treatment method with less adverse reactions than β blocker.

关 键 词：血管紧张素Ⅱ受体拮抗剂 Β受体阻滞剂 美托洛尔 厄贝沙坦 血管迷走性晕厥 

分 类 号：R459.7[医药卫生—急诊医学]